Doctors have since time in memorial tried to combat cancer no matter what it would cost. However, at some point, it’s like the enthusiasm for who will cure the disease outright first –slowed down as cancerous cells proved to grow in stubbornness year after year.
However, after the boom in artificial intelligence technology, it’s like the race for finding cancer cures sparked again, and this time around the passion is blazing hot among scientist.
Fighting Cancer Through Artificial Intelligence
A week ago, a team of scientists created AI driven nanorobots, meant to be injected into the blood circulatory system, to go shrink cancerous tumors by blocking their source of blood. The experiment worked out perfectly on rats and it’s awaiting approval for human use.
Now, doctors are taking a different approach that focuses on machine learning to develop precision cancer medicine. That ideally means using data that is only original to a patient to create an accurate treatment procedure for them.
Is the Approach Viable?
Yes, according to findings, a patient’s own molecular information which in this case is tagged as data, can be matched smartly with artificial intelligence techniques to help doctors learn the patient’s combinatorial multi-drug therapy; that would perfectly work with the victim -alone.
In simpler words, the system will be able to deal with individual patients, to advise on what would work best on the affected with the sole intent of mastering their therapeutical strategies as that would limit incidences of drug resistance.
This concept is likelier than not to come to fruition because, for one, there is always enough data on cancer patients from frequent hospital visits, compared to most ailments. The type of data required here would be the medical history of the patient which can include the relationship with certain drugs, gene history, nature of therapy sessions attended, integrating genome and so on…
Algorithmic Analysis of the Data
To be precise, this concept is in the process of testing. The success rate is expected to be huge because it involves 4 Finish firms named Orion Pharma, Misvik Biology Euformatics and Medi Sapiens.
Now, the teams will be using Combio’s recently built algorithm to pinpoint sets of drugs and inhibitors that offer higher chances of therapeutic effect on the patient.
In projects like these, hurdles often show up in form of data credibility or viability. However, in this case, the researchers will be siphoning their data from Moffitt Cancer Research Center based in the US, Tampa. The center is known for having a large patient data as well as extensive validation capabilities.
This Would Mean More Approached for Curing Cancer
If this research succeeds, the application will be much faster because it involves humans directly; as in, no rats or other related specimens. In addition, patients will have more options on how their brain cancer, lung cancer or blood cancer should be treated.
It is also possible that as research advances in this area of AI application, they will be able to discover the exact survival mechanism that cancer uses to stay alive in its host’s body, to find ways of weakening that.